X0508 4 2023-08-09 0001042074 CymaBay Therapeutics, Inc. CBAY 0001705745 Menold Daniel C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560 0 1 0 0 Vice President, Finance 1 Common Stock 2023-08-09 4 M 0 20945 5.00 A 20945 D Common Stock 2023-08-09 4 S 0 20945 12.3535 D 0 D Employee Stock Option (right to buy) 5.00 2023-08-09 4 M 0 14459 0 D 2024-01-21 Common Stock 14459 0 D Stock Appreciation Right 5.00 2023-08-09 4 M 0 6486 0 D 2024-01-21 Common Stock 6486 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on April 10, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.17 to $12.66, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares subject to the option became vested and exercisable according to the following schedule: 25% of the shares subject to the option vested on the first anniversary of the grant date, and the remaining shares vested in equal monthly installments over the next 36 months. This incentive award (the "Award") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date. /s/ Paul Quinlan, as attorney-in-fact for Daniel Menold 2023-08-11